首页> 外国专利> SYSTEM FOR THE ADAPTATION OF CELL-BASED ASSAYS FOR ANALYSIS ON AUTOMATED IMMUNO-ASSAY PLATFORMS

SYSTEM FOR THE ADAPTATION OF CELL-BASED ASSAYS FOR ANALYSIS ON AUTOMATED IMMUNO-ASSAY PLATFORMS

机译:用于自动免疫分析平台分析的基于细胞的分析自适应系统

摘要

Cell based assays are required for the detection of biological activity and hence are required for use as potency assays, detection of neutralizing antibodies and detection and quantification of the effector cell function of therapeutic antibodies or the quantification of the potency or neutralizing antibody response to virus vectors such as AAV vectors used in gene therapy. Cell-based assay are also required for the quantification of antibody mediated effector functions including complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and antibody- dependent cell-mediated cytotoxicity (ADCC). Cell based assays are difficult to adapt for use on automated immuno-assay platforms. Reporter-genes that encode readily visible proteins that can be quantified using fluorescence or luminescence such as luciferases (firefly, Renilla, Gaussia, Nano Luciferase etc), fluorescent proteins such as green fluorescent protein (GFP) or dsRED or an enzyme such as chloramphenicol acetyltransferase (CAT) or a protease and respond to signal transduction, that is directly related to the mechanism of action of a drug, can be used to quantify the potency of a drug following binding of a drug to a soluble target or cell surface target (receptor or other cell-surface molecule), anti-drug neutralizing antibodies, and therapeutic antibody induced effector cell function. The principal of the invention is that reporter-gene product or by-product produced either during the course of the cell-based assay or onconclusion of the cell based assay is quantified either in the cell medium or cell supernatant, for a secreted protein, or following lysis of the cells with a suitable passive lysis buffer. The reporter- gene product such as firefly luciferase is then detected in the cell medium or cell supernatant or cell lysate using an antibody pair (monoclonal or polyclonal) specific for the gene product such as a firefly luciferase labelled with the dual detection system specific for an ELISA or a particular automated assay platform such as Meso Scale Discovery electro- chemiluminescence (MSD-ECL), Luminex, SMC, Alpco, AlphaLISA, Gyros or label free detection using SPR such as the Biacore platform. The expression of the reporter-gene product such as firefly luciferase can be normalized with respect to the expression of a second reporter gene product such as Renilla luciferase or Nano Luciferase under the control of a constitutive promoter.
机译:基于细胞的测定是检测生物活性所必需的,因此需要用作效能测定,中和抗体的检测以及治疗抗体的效应细胞功能的检测和定量,或者对病毒载体的效能或中和抗体应答的定量例如用于基因治疗的AAV载体。还需要基于细胞的测定来定量抗体介导的效应子功能,包括补体依赖性细胞毒性(CDC),抗体依赖性细胞吞噬作用(ADCP)和抗体依赖性细胞介导的细胞毒性(ADCC)。基于细胞的测定法很难适应在自动化免疫测定平台上使用。记者基因编码的可见基因可以使用荧光或发光定量,例如荧光素酶(萤火虫,雷尼利亚,高斯,纳米荧光素酶等),荧光蛋白(例如绿色荧光蛋白(GFP)或dsRED)或酶(例如氯霉素乙酰转移酶) (CAT)或蛋白酶,并且对信号转导有反应,与药物的作用机制直接相关,可用于量化药物与可溶性靶标或细胞表面靶标(受体)结合后的药物效价或其他细胞表面分子),抗药物中和抗体和治疗性抗体诱导的效应细胞功能。本发明的原理是在细胞培养基或细胞上清液中,对基于细胞的测定过程中或基于细胞的测定结束时产生的报告基因产物或副产物进行定量,以测定分泌的蛋白质或然后用合适的被动裂解缓冲液裂解细胞。然后使用对基因产物有特异性的抗体对(单克隆或多克隆),在萤火虫荧光素酶等报告基因产物中检测到该细胞培养基或细胞上清液或细胞裂解液中,该萤火虫荧光素酶用一种特异于该抗体的双重检测系统标记ELISA或特定的自动化测定平台(例如Meso Scale Discovery电化学发光(MSD-ECL),Luminex,SMC,Alpco,AlphaLISA,Gyros)或使用SPR的无标记检测(例如Biacore平台)。可以相对于组成型启动子控制下的第二种报道基因产品如海肾萤光素酶或纳米萤光素酶的表达来标准化报道基因产物如萤火虫荧光素酶的表达。

著录项

  • 公开/公告号WO2018185301A1

    专利类型

  • 公开/公告日2018-10-11

    原文格式PDF

  • 申请/专利权人 EURO-DIAGNOSTICA AB;

    申请/专利号WO2018EP58890

  • 发明设计人 TOVEY MICHAEL;LALLEMAND CHRISTOPHE;

    申请日2018-04-06

  • 分类号C07K16/24;G01N33/50;G01N33/68;C07K14/715;C07K14/47;C12Q1/6897;

  • 国家 WO

  • 入库时间 2022-08-21 12:42:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号